Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05853354 · ClinicalTrials.gov registry record · Phase 3

Comparative Efficacy, Safety, PK, and Immunogenicity Study

A Phase 3 study of Osteoporosis, Postmenopausal, sponsored by Luye Pharma Group.

Active
Registry status
Phase 3
Development phase
392
Enrollment target
20
Study locations

NCT05853354: Active Phase 3 study of Osteoporosis, Postmenopausal, sponsored by Luye Pharma Group.

NCT05853354 is a Phase 3 study of Osteoporosis, Postmenopausal that is active but no longer recruiting, run by Luye Pharma Group. The registered enrollment target is 392 participants, below the 2,701-participant average among 12 other Osteoporosis, Postmenopausal trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05853354, a Phase 3 study of Osteoporosis, Postmenopausal, is active but no longer recruiting, sponsored by Luye Pharma Group.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
392 participants
Enrollment target
20
Study locations

Study Summary

this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.

Interventions

  • BIOLOGICAL Denosumab

Study Locations (20)

Other

  • MHAT Dr. Atanas Dafovski AD - Kardzhali
  • Medical Centre Leo Clinic EOOD - Plovdiv
  • Diagnostic-consultative center Ascendent EOOD - Sofia
  • Medical Center Leo Clinic EOOD - Varna
  • CCR Brno s.r.o. - Brno
  • Synexus Prague - Prague

Hukuoka

  • Asakawa Orthopedic Clinic - Chikugo
  • Obase Hospital - Orthopedics - Miyako-gun
  • Himeno Hospital - Yame-gun

Tôkyô

  • Med Teda Ooimachi Orthopaedic - Shinagawa-ku
  • Koenji Orthopedic Surgery - Shinagawa-ku

California

  • Clinical Trials Management Services, LLC - Thousand Oaks

Florida

  • Indago Research and Health Center, Inc. - Hialeah

Texas

  • Valley Institute of Research - Fort Worth

Gihu

  • Gifu Prefectural General Med C. - Gifu

Nagano

  • Marunouchi Hospital - Matsumoto-shi

Trial Details

FieldValue
Enrollment Target 392 participants
Start Date 2023-04-05
Est. Completion 2025-12-30
Phase Phase 3
Luye Pharma Group

22 total trials

What the registry record for NCT05853354 still lists

NCT05853354 is an interventional study that assigns participants to a tested intervention. The registered 392 participants enrollment target is mid-sized for trials with a published cap, below the 2,701-participant average among 12 other Osteoporosis, Postmenopausal trials with a reported enrollment target (85% lower).

The record links to 1 condition, with Osteoporosis, Postmenopausal appearing as the primary indexed condition, and to 1 intervention - of which Denosumab is the first listed.

NCT05853354 names 20 study sites across 12 states, led by Other, Hukuoka, Tôkyô.

Frequently Asked Questions

What is clinical trial NCT05853354 about?

NCT05853354 is a clinical study titled "Comparative Efficacy, Safety, PK, and Immunogenicity Study". this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.

What is the current status of trial NCT05853354?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 392 participants. The study started on 2023-04-05. Estimated completion is 2025-12-30.

What conditions does trial NCT05853354 study?

This clinical trial studies the following conditions: Osteoporosis, Postmenopausal.

What interventions are being tested in trial NCT05853354?

The interventions under investigation include: Denosumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT05853354?

This trial is sponsored by Luye Pharma Group, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05853354 being conducted?

This trial has 20 study locations across California, Florida, Texas, Gihu, Hukuoka. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoporosis, Postmenopausal

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05853354's enrollment target sits among peer trials

392 3rd of 12 higher than 10 of 12 other Osteoporosis, Postmenopausal trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoporosis, Postmenopausal trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06397703 · 392 participants · Phase 2

    ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

  • NCT06625775 · 392 participants · Phase 1

    Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

  • NCT07220967 · 392 participants · Phase 4

    A Study of Antibiotic Delivery to Prevent Infection After Breast Tissue Expander Placement

  • NCT07290036 · 392 participants · Phase 1

    A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05853354, the US trial registry maintained by the National Library of Medicine. NCT05853354 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.